Weeks in­to CEO shake­up, Mi­rati bids adieu to a pair of C-suit­ers with KRAS drug fil­ing around the cor­ner

Mi­rati is on the cusp of emerg­ing as the sole chal­lenger against Am­gen in the sud­den­ly hot KRAS in­hibitor mar­ket and thinks it has the man to take it across the fin­ish line. But new lead­er­ship of­ten means shake­ups, and now two Mi­rati ex­ecs are be­ing shown the door.

Mi­rati CMO Joseph Lev­eque and Daniel Fa­ga, the biotech’s chief op­er­at­ing of­fi­cer and prin­ci­pal fi­nan­cial of­fi­cer, have both de­part­ed the com­pa­ny as it en­ters the home­stretch for fil­ing its KRAS drug ada­gra­sib with the FDA, Mi­rati re­vealed in an SEC fil­ing Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER